Search Results - Jesse Fishman

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    P757: INCIDENCE RATES OF HEALTHCARE RESOURCE UTILIZATION AND HEMOGLOBIN LEVELS DURING OPERA: A REAL-WORLD STUDY OF PEGCETACOPLAN TREATMENT IN US ADULTS WITH PAROXYSMAL NOCTURNAL HE... by Jesse Fishman, Jinny Min, Lily Arnett, Apeksha Shenoy

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  2. 2

    Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH by Jesse Fishman, Victoria Higgins, James Piercy, James Pike

    Published in Health and Quality of Life Outcomes (2023-10-01)
    Get full text
    Article


  3. 3

    Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment by Jesse Fishman, Seri Anderson, Sandra E. Talbird, David Dingli

    Published in Hematology Reports (2023-10-01)
    Get full text
    Article


  4. 4

    The cost–effectiveness of pegcetacoplan in complement treatment-naive adults with paroxysmal nocturnal hemoglobinuria in the USA by Jesse Fishman, Koo Wilson, Aleksandra Drzewiecka, Michal Pochopien, David Dingli

    Article


  5. 5

    A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol by Jesse Fishman, Theresa Alexander, Yestle Kim, Patricia Mendez, Iris Kindt

    Article


  6. 6

    Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017–2020 by Jonathan J. Woolley, Jesse Fishman, Christina M. Parrinello, Tom O’Connell

    Published in PLoS ONE (2024-01-01)
    Get full text
    Article


  7. 7

    Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a... by Jesse Fishman, Seth Kuranz, Michael M. Yeh, Kaylen Brzozowski, Herman Chen

    Published in Hematology Reports (2023-04-01)
    Get full text
    Article


  8. 8

    Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France by Piotr Wojciechowski, Marlena Wdowiak, Zalmai Hakimi, Koo Wilson, Jesse Fishman, Jameel Nazir, Mondher Toumi

    Article


  9. 9

    Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests by Jesse Fishman, Tom O'Connell, Christina M. Parrinello, Jonathan J. Woolley, Eric Bercaw, Michael R. Charlton

    Get full text
    Article


  10. 10

    PB2043: CLINICAL EFFECTIVENESS, TREATMENT USE, SATISFACTION AND IMPACT ON QUALITY-OF-LIFE OF PEGCETACOPLAN TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH). by Koo Wilson, Carly Rich, Zalmai Hakimi, Jesse Fishman, Jennifer Mellor, Lucy Earl, Yasmin Taylor, Alice Simons, Joe Conyers, Alexander Röth

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  11. 11

    The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective by Flore Sicre de Fontbrune, Pascale Burmester, Maria Piggin, Joana E. Matos, Halley Costantino, Koo Wilson, Zalmai Hakimi, Jameel Nazir, Renaud Desgraz, Jesse Fishman, Emmelie Persson, Jens Panse

    Published in Hematology (2022-12-01)
    Get full text
    Article


Search Tools: